NICO incorporates in October.
$2.83 Million Raised
NICO began organizing as a company in April with it’s initial business plan developed, $2.83 million raised, contract manufacturers were selected, its first product – the NICO Myriad — was produced.
The first employees of the company were hired to support the engineering, sales and marketing of the Myriad; $10 million in capital funding was raised and the 15 gauge Myriad product was commercially launched.
11 Gauge Myriad
Surgeon demand generated the production of the 11 gauge Myriad.
A significant validation year with three Myriad clinical papers published, approval of the Myriad CE Mark, registration approval of the Myriad in Canada and Australia, international distribution agreements signed for sales in Australia and Canada, and three new products launched.
A milestone year with the commercial launch of the NICO BrainPath, three 6 Pillar Approach courses held with more than 40 physicians trained, started an intercerebral hemorrhage (ICH) study called MiSPACE (Minimally invasive Subcortical Parafascicular Access for Clot Evacuation, a physician initiated prospective multi-center, economic and outcome registry with the purpose of determining clinical outcomes of the parafascicular minimally invasive clot evacuation technique for spontaneous ICH), grew sales 66% over 2011, raised $6.57 million in capital, and more than 50% of the top 40 U.S. hospitals are using Myriad.
More than 100 surgeons trained on the 6 Pillar Approach, 21 hospitals become designated BrainPath Centers, NICO received the John Kerry Award, four abstracts highlighting BrainPath are presented at conferences, the BrainPath ST Gold product is launched, the company achieves its first $3 million quarter in sales, and the first patients are enrolled in MiSPACE (Minimally invasive Subcortical Parafascicular Access for Clot Evacuation, a physician initiated, prospective multi-center, economic and outcome registry with the purpose of determining clinical outcomes of the parafascicular minimally invasive clot evacuation technique for spontaneous ICH).
Multi-center 35 patient study shows statistically significant functional recovery in the right patients with 90% evacuation and no new deficits or surgical mortalities when using BrainPath to address ICHs, more than 1,000 BrainPath procedures completed, the Myriad is used in 87% of all BrainPath cases, surgical experiences and patient outcomes using BrainPath published in three publications and three abstracts presented, four 6 Pillar Approach courses held, BrainPath economic results published, NICO receives the Indiana Innovation Award, national partnership agreement signed with the National Brain Tumor Society , and NICO now has more than 300 patents issued or pending worldwide.
BrainPath surgical results published in 12 abstracts, 3 peer-reviewed publications, and 7 presentations, more than 2,000 BrainPath procedures completed, BrainPath CE Mark approved, amended Myriad CE Mark approved, FDA clears more specific indications for BrainPath, statewide ICH educational events featuring BrainPath held in Indianapolis, Boston and Atlanta, and BrainPath patient featured on The Doctors national TV program, Capitol Hill, and WABC Radio.
- More Exciting Milestones Yet to Come!
From Start-Up to Innovative Leader